We conducted an observational study to assess the etiology, clinical features and outcomes of bloodstream infection (BSI) in 172 hematopoietic SCT (HCST) recipients. One hundred episodes of BSI in the pre-engraftment period (early onset) were compared with 89 episodes in the post-engraftment phase (late onset). More patients with late-onset BSI received an allogeneic HSCT, had GVHD and had received corticosteroids, whereas patients with early-onset BSI were more likely to have neutropenia, severe mucositis and a central venous catheter (CVC) in place. CVC was the most frequent site of infection, followed by an endogenous source. Pneumonia and gastrointestinal infection were particularly frequent in late-onset BSI, whereas mucositis was more frequent in the early-onset group. Gram-positive organisms predominated over Gram negatives. Streptococcus pneumoniae was more frequent in patients with late-onset BSI. Patients with late-onset BSI presented worse outcomes regarding septic shock, intensive care unit admission and early and overall case-fatality rates. Early-onset BSI was mainly related to the presence of neutropenia, mucositis and CVC, whereas late-onset BSI mainly affected severely immunosuppressed allogeneic HSCT recipients with GVHD and corticosteroids. Late-onset BSI caused high case-fatality rates. BSI due to S. pneumoniae was especially frequent late after transplantation. The development of better vaccination strategies is needed.
INTRODUCTION
Bloodstream infection (BSI) is a major cause of morbidity and mortality in patients undergoing hematopoietic SCT (HSCT), with an incidence ranging between 13 and 60%. [1] [2] [3] [4] BSI in HSCT recipients has mainly been described in the pre-engraftment period, when neutropenia and mucosal damage represent the most important predisposing factors for BSI; however, BSI may also occur post-engraftment, when it is associated with other risk factors. 2, 3, 5 The epidemiology, clinical characteristics and etiology of BSI in HSCT recipients may vary depending on the time since transplantation. Nevertheless, the differences between infections occurring pre-and post-engraftment have not been fully described. 2, 6 Most published articles regarding BSI in HSCT recipients are retrospective and/or focus on subjects who underwent transplantation in the 1990 s. 3, [5] [6] [7] [8] [9] [10] Since then, there have been changes in the care of HSCT recipients, such as the introduction of different types of donors, different immunosuppression, conditioning chemotherapy including reduced-intensity regimens, and so on. Furthermore, changes in the etiology of BSI in cancer patients have recently been described. Since the early 1960 s, when the importance of Gram-negative BSI among neutropenic cancer patients was first identified, the etiology of BSI in this patient population became predominantly Gram-positive. 11 At our center, we have observed a shift toward more Gram-negative infecting organisms in neutropenic cancer patients with BSI in recent years, as well as an increase in multidrug-resistant Gram-negative bacilli over time. 12 However, current and prospective information regarding the etiology and antimicrobial resistance of BSI in the specific group of patients undergoing HSCT is scarce. 1, 4, 8, 13 The present study was performed to determine the etiology, current clinical features and outcomes of BSI in a more recent prospective cohort of adult HSCT recipients, and to identify differences between those episodes occurring in the pre-engraftment and postengraftment periods. A better understanding of these characteristics may help to optimize the management of patients in the transplant setting.
MATERIALS AND METHODS
Setting, patients and study design regarding these episodes is prospectively collected and recorded in a specific data base.
Ethics statement
This observational study was approved by the Institutional Review Board Ethics Committee of Clinical Research-Hospital Universitari de Bellvitge, with the following reference number PR 232/10. To protect personal privacy, information identifying each patient in the electronic database was encrypted. Informed consent was waived by the Clinical Research Ethics Committee because no intervention was involved and no patientidentifying information was included.
Definitions
Neutropenia was defined as an absolute neutrophil count o 500/mm 3 . The criterion for engraftment was an absolute neutrophil count of 500/mm 3 or more for 3 consecutive days. Current corticosteroid therapy was recorded when a patient was receiving corticosteroids at the time of the BSI episode or in the previous month. Prior antibiotic therapy was defined as the receipt of any systemic antibiotic for >48 h during the previous month. Acute and/or chronic GVHD was included as a risk factor for analysis of BSI in patients in whom systemic immunosuppression was required for management, according to standard criteria. 14, 15 BSI was considered to be from an endogenous source in patients with neutropenia in whom no other BSI sites were identified. In patients without neutropenia, an unknown source was considered if no evident origin of the infection was identified. Bacteremia was considered to be catheter related when the causative agent isolated in the blood was also recovered in a catheter hub or in the catheter tip.
BSI caused by coagulase-negative staphylococci (CNS) and other potential skin contaminants was considered to be significant when they were identified in at least two blood cultures or in one blood culture and in one other site. The following Gram-negative bacilli were considered to be multidrug resistant: (a) extended spectrum β-lactamase-producing Enterobacteriaceae, (b) AmpC cephalosporinase-hyperproducing Enterobacteriaceae, (c) microorganisms with intrinsic-resistance mechanisms, such as Stenotrophomonas maltophilia, and d) multidrug-resistant strains including Pseudomonas aeruginosa and Acinetobacter baumannii. Multidrug-resistant strains were defined as those resistant to three or more classes of antibiotics: carbapenems (imipenem, meropenem), penicillins (piperacillin, ticarcillin, piperacillin-tazobactam), cephalosporins (ceftazidime and cefepime), monobactams, aminoglycosides and fluoroquinolones. 16 Shock was defined as a systolic pressure o90 mm Hg, which was unresponsive to fluid treatment or which required vasoactive drug therapy. Empirical antibiotic therapy was considered inadequate if the treatment regimen did not include at least one antibiotic active in vitro against the infecting microorganism. Early case-fatality rate was defined as death within 48 h of the BSI episode. Overall case-fatality rate was defined as death by any cause within the first 30 days of the onset of BSI.
Transplantation procedures and management of infections
Transplantation was performed according to institutional protocols. Briefly, the most frequent myeloablative conditioning included total-body irradiation and cyclophosphamide. Reduced-intensity conditioning included fludarabine with either busulfan or melphalan. Standard GVHD prophylaxis included cyclosporine and methotrexate. Low-dose anti-thymocyte globulin (2 mg/kg days − 2 and − 1) was used in unrelated donors, and corticosteroids rather than methotrexate were used in patients receiving cord blood transplantation. From 2006 to June 2011 no universal antibacterial prophylaxis was given to patients receiving HSCT. After July 2011, ciprofloxacin was given to all patients receiving allogeneic transplantation for 60 days after transplant, in an attempt to prevent polyomavirus BK virus-associated hemorrhagic cystitis. 17 Antifungal prophylaxis with fluconazole was given to patients undergoing autologous HSCT, and posaconazole was given to those receiving allogeneic transplantation. 18 From engraftment until the end of immunosuppressive therapy and immunologic recovery, prophylaxis against Pneumocystis jirovecii and herpetic infections was provided, with trimethoprim-sulfametoxazole and acyclovir, respectively. Before engraftment patients received prophylaxis against P. jirovecii with nebulized pentamidin. No antibacterial prophylaxis with penicillin or other antibiotics against Streptococcus pneumoniae was administered to patients receiving HSCT. The time when the patients started the post-transplant immunization schedule varied, depending on the type of transplant, the presence of chronic GVHD and the immunosuppression status. All patients were cared for in single rooms with positive pressure and high-efficiency particulate air filtration.
Following the institution's standard policy, empirical antibiotic therapy for febrile neutropenia episodes was cefepime (or imipenem) plus amikacin. The aminoglycoside was usually stopped after 48 h, on the advice of the physician of infectious disease.
Microbiological studies
Two sets of two blood samples (Bactec Plus Aerobic and Anaerobic, Becton Dickinson, New Jersey, NJ, USA), taken 30 min apart and each containing 8-10 ml of blood, were drawn from patients who presented fever ⩾ 38°C or when BSI was suspected based on any clinical sign or symptom. Blood samples were processed by the BACTEC 9240 system (Becton-Dickinson Microbiology Systems) with an incubation period of 5 days. Positive blood samples were sub-cultured onto chocolate agar. Microbial identification was performed using commercially available panels (MicroScan (Siemens, Dade Behring Inc., West Sacramento, CA, USA) or Vitek (BioMérieux, Marcy l'Etoile, France), by standard biochemical and /or enzymatic test or by matrix-assisted laser desorption ionization (MALDI-TOF; Bruker Daltonics, Billerica, MA, USA).
Antibiotic susceptibility was tested using the microdilution method following Clinical Laboratory Standard Institute guidelines. The antimicrobial susceptibility of isolates was interpreted according to current Clinical Laboratory Standard Institute criteria. 19 The screening of multidrugresistant phenotypes including Methicillin-resistant Staphylococcus aureus, ampicillin-and vancomycin-resistant enterococci, extended-spectrum β-lactamase production and carbapenemase production was conducted according to Clinical Laboratory Standard Institute recommendations. 20, 21 Statistical analysis Continuous variables were compared by means of the Mann-Whitney U-test and t-test. Qualitative variables were compared using the χ 2 -test, and odds ratios (OR) and 95% confidence intervals (CI) were calculated. Multivariate conditional logistic regression analysis of factors potentially associated with mortality included all statistically significant variables in the univariate analysis, sex and age, and all clinically important variables regardless of whether they were statistically significant or not. 22 This analysis was performed with the stepwise logistic regression model of the SPSS software package (SPSS v. 17, Chicago, IL, USA).
RESULTS
During the study period, a total of 400 HSC transplantations were performed at our center, of which 239 were autologous and 161 were allogeneic. Among them, we documented 189 episodes of BSI among 172 transplant recipients, leading to an overall incidence of BSI of 47.2%. The incidence of BSI was higher in patients who had received an allogeneic transplant (74.5% allogeneic vs 28.8% autologous). One hundred episodes of BSI occurred in the pre-engraftment period and 89 post engraftment. Table 1 shows the epidemiological and clinical characteristics of all episodes of BSI compared by groups. The most common underlying hematological disease was acute leukemia (n = 95, 50%), followed by other lymphoproliferative diseases (n = 73, 39%) such as non-Hodgkin lymphoma (n = 18) and Hodgkin disease (n = 7), multiple myeloma (n = 47) and chronic lymphatic leukemia (n = 1). Other underlying conditions included myelodysplastic syndrome (n = 12), chronic myeloid leukemia (n = 5), meduloblastoma (n = 2), and testicular teratocarcinoma and primary amyloidosis (n = 1).
Patients with early-onset BSI were more likely to present neutropenia, a low-risk MASCC score ⩾ 21, and severe mucositis. They were also more likely to have received transplantation from an unrelated donor, antifungal prophylaxis, previous chemotherapy and radiotherapy, and to have a central venous catheter in place. Patients with late-onset BSI were more frequently recipients of an allogeneic transplantation with GVHD and other comorbidities, and were more likely to have received reduced-intensity conditioning chemotherapy. They had also been administered more antibacterial prophylaxis, previous antibiotic therapy, corticosteroids and cyclosporine, and were more likely to have received parenteral nutrition and to have a urinary catheter in place. The presence of a concomitant infection and shock at onset of bacteremia were also more frequent in this group of patients.
Taking into account the major differences in the postengraftment period between autologous and allogeneic patients from a risk factor point of view, we performed a subanalysis of the post-engraftment period analyzing these two groups of transplant patients separately. Results of this subanalysis are shown in Table 2 .
The most frequent origin of BSI was catheter infection in 42% of cases, followed by an endogenous source in 26% of cases and an unknown source in 9%. BSI originating in the respiratory and gastrointestinal tract was more frequent in the group of late-onset BSI, whereas mucositis was more frequent in the early-onset group. Table 3 shows the most frequent causative agents of all episodes of BSI compared by groups. Overall, Gram-positive organisms predominated over Gram negatives, with CNS being the most frequent Gram positive isolated (57%), followed by S. pneumoniae (11%) and Enterococcus spp (10%). Among Gram negatives, Escherichia coli (64.5%) was the most frequent species isolated, followed by P. aeruginosa (16%) and Klebsiella pneumoniae (14.5%). The only significant difference in etiology between the groups was the higher rate of S. pneumoniae BSI among patients with late-onset BSI. The quinolone-resistance rate among Gram-negative bacilli was 53%, and multidrug resistant Gramnegative bacilli accounted for 21% of the total of episodes of BSI, with no differences between groups.
Outcomes of all HSCT recipients with BSI are detailed in Table 4 . Patients with late-onset BSI less frequently received empirical antibiotic therapy and presented poorer outcome than those with (10) , CMV colitis (1), CMV pneumonia (1), Clostridium difficile colitis (2), disseminated tuberculosis (2), invasive aspergillosis (1), bacterial pneumonia (1), BK virusassociated hemorrhagic cystitis (1), Stenotrophomonas maltophilia tracheobronchitis (1). Three patients presented two concomitant infections, all of them including CMV reactivation.
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early-onset BSI, with a higher need for intensive care unit (ICU) admission and mechanical ventilation, as well as higher early and overall case-fatality rates. Most patients (52%) received a combination antibiotic regimen, mainly cefepime plus amikacin (74% of cases). Cephalosporins and aminoglycosides were therefore the most frequent antibiotics administered in 51 and 44% of patients respectively, followed by carbapenems in 21%. Patients with early-onset BSI more frequently received cephalosporins and aminoglycosides, whereas patients with late-onset BSI more frequently received carbapenems, β-lactam+β-lactam inhibitors and quinolones.
In total, 66 patients received inadequate empirical antibiotic therapy. Among them, 33 (50%) were patients with catheter-related BSI due to CNS who were treated initially with cefepime and amikacin.
Risk factors associated with overall case fatality in the cohort of HSCT recipients with BSI are shown in Table 5 . An allogeneic transplant, the presence of other comorbidities, GVHD, polymicrobial BSI, viridians group streptococci (VGS) BSI, current corticosteroids, concomitant infection, shock at presentation, and need for ICU admission and mechanical ventilation were the variables most frequently found in the group of patients who died. After applying a logistic regression model, the only variables found to be independent of risk factors for overall case-fatality rate were BSI due to VGS (OR 16.14; 95% CI, 1.39-187.61) and ICU admission (OR 21.98; 95% CI, 4.25-113.44).
DISCUSSION
We observed a high incidence of BSI in HSCT recipients, especially in those receiving an allogeneic transplant. This finding is in line with other studies that have found a higher risk of BSI in this specific group of transplant recipients. 3, 7 During the pre-engraftment period, we identified the presence of neutropenia, a central venous catheter and severe mucositis as important risk factors for BSI. During the pre-engraftment phase it is likely that mucosal damage allows bacteria to enter the bloodstream and the lack of neutrophils hampers their effective clearance, thus leading to BSI. Moreover, the presence of a central venous catheter further increases the risk of introducing bacteria contaminating the skin into the bloodstream.
However, we also observed that a consistent number of BSI occurred late after transplantation. The factors associated with late-onset BSI in our study differed markedly from those associated with early-onset BSI, including the presence of GVHD, current corticosteroids, parenteral nutrition and a urinary catheter in place, reflecting a highly immunosuppressed population in need of monitoring and supportive care. Both acute and chronic GVHD are known risk factors for BSI in allogeneic transplant recipients. 6, 9, 23 GVHD may cause profound immunodeficiency with B-and T-cell depletion, impairment of lymphocyte function and neutropenia. 24 Patients with GHVD have also been found to have suboptimal serum opsonizing activity due to the associated hypogammaglobulinemia. 25 In addition, the frequently associated corticosteroid therapy administered to treat GVHD also impairs lymphocyte, monocyte and neutrophil function, increasing the susceptibility to bacterial infection. 26 The presence of a concomitant infection was also more frequent in patients with late-onset BSI. The most frequent concomitant infection was cytomegalovirus reactivation (with or without organ involvement), which has been shown to induce immunosuppression per se, and has also been associated with a higher risk for GVHD. 27 Gram-positive organisms, especially CNS, were the most frequent etiology of BSI in both periods, in agreement with other studies involving HSCT recipients. 3, 5, 10, 28 The frequency of Gram negatives was similar in both groups, as was the rate of multidrug resistance among them. The overall rate of multidrug-resistant Gram-negative bacilli was 21%. Interestingly, the frequency of multidrug-resistant Gram-negative bacilli increased over the study period, rising from 2 isolates between 2006 and 2009 to 11 isolates between 2010 and 2013. The emergence of multidrugresistant Gram-negative bacilli in the transplant setting may MDRGNB, multidrug-resistant Gram-negative bacilli: extended-spectrum β-lactamase-producing Escherichia coli (7), multidrug-resistant Acinetobacter baumannii (2), Stenotrophomonas maltophilia (2), multidrug-resistant Pseudomonas aeruginosa (1), multidrug-resistant Achromobacter xylosoxidans (1). become a clinical concern, as therapeutic options to treat these infections are often very limited. The only significant difference in the etiology of BSI was the higher proportion of BSI due to S. pneumoniae in the late-onset group. Invasive pneumococcal infection is a life-threatening complication that may occur in months to years after HSCT. The incidence of invasive pneumococcal infection in HSCT recipients is higher than in the general population, and the incidence appears to be even higher in those patients receiving allogeneic transplantation, and also in those with chronic GVHD. [29] [30] [31] [32] In our series, 8 out of 13 patients with pneumococcal BSI were allogeneic transplant recipients, and 6 of them had chronic GVHD. The higher rate specifically observed in allogeneic transplant recipients may be due to multiple factors, including post-transplant immunosuppression, the immunomodulatory effects of GVHD, impairment of splenic function and the absence of prior vaccination or a suboptimal vaccine response.
Efforts to prevent invasive pneumococcal infection should include active immunization and antibiotic prophylaxis. The American Society for Blood and Marrow Transplantation Guidelines recommend antibiotic prophylaxis against pneumococcal infection in patients with chronic GVHD and in patients with low IgG levels. Antibiotic prophylaxis should be administered even to patients who have received pneumococcal vaccine; this is because not all strains are included in the vaccines and the immunogenicity of vaccines against the vaccine strains in HCT patients is only around 80% at most. There is also a theoretical concern that strains not included in the vaccine may replace vaccine strains. Oral penicillin remains the preferred choice, but antibiotic selection depends on the local pattern of pneumococcal resistance to penicillin and other antibiotics (that is, secondgeneration cephalosporins, macrolides and quinolones). 33 None of our patients with pneumococcal BSI were receiving antibiotic prophylaxis at the time of BSI. Despite the recommendations, the use of universal antibiotic prophylaxis against S. pneumoniae remains a matter of active debate. Some investigators have found that antibiotic prophylaxis does not prevent invasive pneumococcal infection in all transplant recipients. [30] [31] [32] Moreover, patients' compliance with a regimen involving daily antibiotics for months and years is usually poor. The development of resistance to penicillin and other antibiotics such as macrolides or quinolones is a concern, and the prophylactic approach is more complex in areas where resistance of S. pneumoniae to antibiotics is already a problem. 34 Regarding vaccination, three doses of a conjugate 7-valent vaccine (PCV7), or a more recently licensed 13-valent conjugated vaccine (PCV13), is recommended in all patients receiving an HSCT. 33, 35, 36 A fourth dose with the polysaccharide vaccine (PPSV23) is likely to be beneficial, to broaden the immune response. After that, a fourth dose of the PCV might increase the response rate in patients with chronic GVHD, who are less likely to respond to PPSV23. The time to initiate routine post-transplant vaccination with PCV is controversial. One trial showed similar antibody responses with vaccination started at 3 months (early) and 9 months (late) post transplant. 7 Thus, early vaccination may be preferred as it may protect against both late and early pneumococcal disease. It should be noted that early vaccination may not prime for a PPSV23 boost as efficiently as late vaccination. Also, early vaccination may elicit a shorter antibody response.
In our study, 12 out of 13 episodes of pneumococcal BSI occurred in the post-engraftment period, at a median of 594 days (range, 38-1928 days) after transplantation. Interestingly, only three patients had received the PPSV23 in the 5 years before admission (in two patients information regarding the vaccination status was not available). These data from our series identify an area of improvement to include the 13-valent conjugated vaccine (PCV13) and a fourth dose with the polysaccharide vaccine (PPSV23) as part of our comprehensive vaccination program for transplant recipients.
Fewer patients with BSI in the post-engraftment period received empirical antibiotic therapy. The lower presence of fever at onset of BSI, mainly in those patients receiving corticosteroids for GVHD and other conditions, probably reduced the suspicion of infection. However, the proportion of patients who received an appropriate empirical antibiotic therapy was similar in both periods, as was the time to initial adequate antibiotic therapy. Although inadequate empirical antibiotic therapy has been associated with poor outcome in patients with BSI, 38 we did not find this relationship. A plausible explanation for this finding is that the great majority of patients (50%) who received inappropriate empirical antibiotic therapy had catheter-related Abbreviations: CI = confidence interval; HSCT = hematopoietic SCT; MDRGNB = multidrug-resistant Gram-negative bacilli; OR = odds ratios; VGS = viridians group streptococci. The bold values are those which remained statistically significant in the multivariate analysis.
BSI due to CNS, which is a type of infection associated with a better outcome than other etiologies of BSI. 39 Patients with late-onset BSI presented poorer outcomes with higher early and overall case-fatality rates. Late-onset BSI occurred mainly in allogeneic transplant recipients with GVHD, corticosteroid therapy, concomitant infections and a severely immunosuppressed status. Patients with late-onset BSI also presented more shock and a higher need for ICU admission, which are factors known to be related with poor outcome. Mikulska et al. 13 reported that late BSI (>20 days) in allogeneic transplant recipients was associated with higher mortality, together with relapsed disease at time of transplantation. It appears that patients' baseline situation and their immunosuppression status may play a pivotal role in mortality.
The only variables associated with overall case-fatality rate in the multivariate analysis were BSI due to VGS and ICU admission. Immunosuppressed patients with BSI admitted to the ICU for severe sepsis and/or unresponsive septic shock represent the worst scenario, with a high risk for further complications and multiorgan failure. The association between VGS BSI and mortality has been previously reported by some investigators, mainly patients presenting with septic shock and/or acute respiratory distress syndrome. 2, 40 This complication occurs in 3-33% of patients, with mortality rates ranging from 6-30%. Almyroudis et al. found a 24% attributable mortality in allogeneic transplant recipients with VGS BSI in the pre-engraftment period. All patients developed acute respiratory distress syndrome and multiorgan system failure. 2 In our study, five patients with VGS BSI died: three had polymicrobial BSI (with E. coli in two patients and P. aeruginosa in one), and two of them died from septic shock. Out of two other patients with monomicrobial VGS infection, one also died from septic shock.
A limitation of our study is that it was performed at a single institution, and the results may not reflect the epidemiology of different centers and/or different geographical areas. However, it also has certain strengths. It describes the most important characteristics of BSI in a retrospective current cohort of high risk transplant recipients, and it highlights the differences between those episodes occurring early and late after transplantation.
In conclusion, we found that early-onset BSI is mainly related to the presence of neutropenia, mucositis and an indwelling central venous catheter, whereas late-onset BSI predominantly involves severely immunosuppressed allogeneic transplant recipients with GVHD and corticosteroids. BSI occurring late after transplantation is associated with high morbidity and high case-fatality rates. BSI due to S. pneumoniae was especially frequent late after transplantation, and the vaccination rate in these patients was very low. The development of more comprehensive and optimal vaccination strategies is needed to decrease the risk of invasive disease in these high risk patients.
